Details for Patent: 10,149,829
✉ Email this page to a colleague
Which drugs does patent 10,149,829 protect, and when does it expire?
Patent 10,149,829 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has one hundred and forty-seven patent family members in twenty-three countries.
Summary for Patent: 10,149,829
| Title: | Treatment of circadian rhythm disorders |
| Abstract: | Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. |
| Inventor(s): | Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD) |
| Assignee: | Vanda Pharmaceuticals Inc. (Washington, DC) |
| Application Number: | 15/382,526 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,149,829 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,149,829
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS | ⤷ Try a Trial | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS | ⤷ Try a Trial | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,149,829
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013211878 | ⤷ Try a Trial | |||
| Australia | 2013211880 | ⤷ Try a Trial | |||
| Australia | 2013361459 | ⤷ Try a Trial | |||
| Australia | 2015206797 | ⤷ Try a Trial | |||
| Australia | 2016204178 | ⤷ Try a Trial | |||
| Australia | 2016204217 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
